BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35680938)

  • 1. Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity.
    Kong R; Qian X; Ying W
    Sci Data; 2022 Jun; 9(1):283. PubMed ID: 35680938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells.
    Chen YW; Liu JY; Lin ST; Li JM; Huang SH; Chen JY; Wu JY; Kuo CC; Wu CL; Lu YC; Chen YH; Fan CY; Huang PC; Law CH; Lyu PC; Chou HC; Chan HL
    Mol Biosyst; 2011 Nov; 7(11):3065-74. PubMed ID: 21894339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
    Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
    Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
    Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
    Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ribosomal associated protein hnRNP D in gemcitabine-resistant pancreatic cancer.
    Wang C; Huang H
    Biochem Biophys Res Commun; 2021 Nov; 579():181-187. PubMed ID: 34624736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
    Zhou J; Zhang L; Zheng H; Ge W; Huang Y; Yan Y; Zhou X; Zhu W; Kong Y; Ding Y; Wang W
    Cancer Med; 2020 Feb; 9(3):1115-1130. PubMed ID: 31823522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
    Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
    Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
    Arumugam T; Ramachandran V; Fournier KF; Wang H; Marquis L; Abbruzzese JL; Gallick GE; Logsdon CD; McConkey DJ; Choi W
    Cancer Res; 2009 Jul; 69(14):5820-8. PubMed ID: 19584296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.
    Duong HQ; Hong YB; Kim JS; Lee HS; Yi YW; Kim YJ; Wang A; Zhao W; Cho CH; Seong YS; Bae I
    J Cell Mol Med; 2013 Oct; 17(10):1261-70. PubMed ID: 23855452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
    El Amrani M; Corfiotti F; Corvaisier M; Vasseur R; Fulbert M; Skrzypczyk C; Deshorgues AC; Gnemmi V; Tulasne D; Lahdaoui F; Vincent A; Pruvot FR; Van Seuningen I; Huet G; Truant S
    Mol Carcinog; 2019 Nov; 58(11):1985-1997. PubMed ID: 31373074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
    Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
    Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
    Blaauboer A; Booy S; van Koetsveld PM; Karels B; Dogan F; van Zwienen S; van Eijck CHJ; Hofland LJ
    BMC Cancer; 2020 Sep; 20(1):913. PubMed ID: 32967656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
    Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
    Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
    Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
    Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.
    Pan X; Arumugam T; Yamamoto T; Levin PA; Ramachandran V; Ji B; Lopez-Berestein G; Vivas-Mejia PE; Sood AK; McConkey DJ; Logsdon CD
    Clin Cancer Res; 2008 Dec; 14(24):8143-51. PubMed ID: 19088029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
    Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
    Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
    Ma G; Sun Y; Fu S
    Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.